130 related articles for article (PubMed ID: 21817806)
1. Intensively lowering both low-density lipoprotein cholesterol and blood pressure does not reduce cardiovascular risk in Japanese coronary artery disease patients.
Kohro T; Yamazaki T; Izumi T; Daida H; Kurabayashi M; Miyauchi K; Tojo T; Nagai R;
Circ J; 2011; 75(9):2062-70. PubMed ID: 21817806
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure, low-density lipoprotein cholesterol, and incidences of coronary artery disease and ischemic stroke in Japanese: the Suita study.
Tsukinoki R; Okamura T; Watanabe M; Kokubo Y; Higashiyama A; Nishimura K; Takegami M; Murakami Y; Okayama A; Miyamoto Y
Am J Hypertens; 2014 Nov; 27(11):1362-9. PubMed ID: 24713850
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a study to examine lower targets for low-density lipoprotein-cholesterol and blood pressure in coronary artery disease patients.
Nagai R; Izumi T; Kurabayashi M; Daida H; Tojo T; Hasegawa A; Miyauchi K; Hayashi D; Kohro T; Okada Y; Yamazaki T;
Circ J; 2008 Apr; 72(4):515-20. PubMed ID: 18362418
[TBL] [Abstract][Full Text] [Related]
4. Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL.
Fujihara Y; Nakamura T; Horikoshi T; Obata JE; Fujioka D; Watanabe Y; Watanabe K; Kugiyama K
Circ J; 2019 May; 83(6):1302-1308. PubMed ID: 30996151
[TBL] [Abstract][Full Text] [Related]
5. Intensive LOwering of BlOod pressure and low-density lipoprotein ChOlesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease.
Takamiya Y; Miura S; Kawamura A; Tanigawa H; Zhang B; Iwata A; Nishikawa H; Matsuo K; Shirai K; Saku K
Coron Artery Dis; 2009 Jun; 20(4):288-94. PubMed ID: 19440067
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
[TBL] [Abstract][Full Text] [Related]
7. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
8. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
Bauters C; Tricot O; Lemesle G; Meurice T; Hennebert O; Farnier M; Lamblin N
Arch Cardiovasc Dis; 2018 Nov; 111(11):634-643. PubMed ID: 29198936
[TBL] [Abstract][Full Text] [Related]
9. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2.
Natsuaki M; Furukawa Y; Morimoto T; Nakagawa Y; Ono K; Kaburagi S; Inada T; Mitsuoka H; Taniguchi R; Nakano A; Kita T; Sakata R; Kimura T;
Circ J; 2012; 76(6):1369-79. PubMed ID: 22447012
[TBL] [Abstract][Full Text] [Related]
10. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K; Sasako T; Okazaki Y; Kato M; Okahata S; Katsuyama H; Haraguchi M; Morita A; Ohashi K; Hara K; Morise A; Izumi K; Ishizuka N; Ohashi Y; Noda M; Kadowaki T;
Lancet Diabetes Endocrinol; 2017 Dec; 5(12):951-964. PubMed ID: 29079252
[TBL] [Abstract][Full Text] [Related]
11. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
Bangalore S; Breazna A; DeMicco DA; Wun CC; Messerli FH;
J Am Coll Cardiol; 2015 Apr; 65(15):1539-48. PubMed ID: 25881936
[TBL] [Abstract][Full Text] [Related]
12. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
[TBL] [Abstract][Full Text] [Related]
13. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
[TBL] [Abstract][Full Text] [Related]
14. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.
Kostis JB; Breazna A; Deedwania PC; LaRosa JC;
J Clin Hypertens (Greenwich); 2008 May; 10(5):367-76. PubMed ID: 18453796
[TBL] [Abstract][Full Text] [Related]
15. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
[TBL] [Abstract][Full Text] [Related]
16. Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study.
Ur E; Langer A; Rabkin SW; Calciu CD; Leiter LA;
Can J Cardiol; 2010 Feb; 26(2):80-6. PubMed ID: 20151053
[TBL] [Abstract][Full Text] [Related]
17. High-Density Lipoprotein Cholesterol and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Statins: An Observation from the REAL-CAD Study.
Omote K; Yokota I; Nagai T; Sakuma I; Nakagawa Y; Kamiya K; Iwata H; Miyauchi K; Ozaki Y; Hibi K; Hiro T; Fukumoto Y; Mori H; Hokimoto S; Ohashi Y; Ohtsu H; Ogawa H; Daida H; Iimuro S; Shimokawa H; Saito Y; Kimura T; Matsuzaki M; Nagai R; Anzai T
J Atheroscler Thromb; 2022 Jan; 29(1):50-68. PubMed ID: 33431716
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
19. Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization.
Farkouh ME; Godoy LC; Brooks MM; Mancini GBJ; Vlachos H; Bittner VA; Chaitman BR; Siami FS; Hartigan PM; Frye RL; Boden WE; Fuster V
J Am Coll Cardiol; 2020 Nov; 76(19):2197-2207. PubMed ID: 33153578
[TBL] [Abstract][Full Text] [Related]
20. Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial.
Miyauchi K; Kimura T; Shimokawa H; Daida H; Iimuro S; Iwata H; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Ohashi Y; Ohtsu H; Saito Y; Matsuzaki M; Nagai R;
Int Heart J; 2018 Mar; 59(2):315-320. PubMed ID: 29503404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
